ReviewCyborg and bionic systems (Washington, D.C.)2024
Advances in Prostate Cancer Biomarkers and Probes.
Review in Cyborg and bionic systems (Washington, D.C.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Ovarian Cancer: New Insight and Future Perspectives.Molecular biotechnology · 2026Review
- Construction and comparison of preeclampsia prediction models using logistic regression and machine learning.BMC medical informatics and decision making · 2026Article
- [Overexpression of lncRNA SNHG12 promotes docetaxel resistance of prostate cancer cells by activating PI3K/AKT signalingNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates.Nutrition and metabolic insights · 2026Review
- Optoelectronic Tweezers for Single-Cell Research: Principles, Applications, and Prospects.Cyborg and bionic systems (Washington, D.C.) · 2026Review
- Adverse histological features are more commonly observed in hypergonadotropic prostate cancer patients.The Canadian journal of urology · 2025Article
- NETs in ovarian cancer progression: innovative nanoparticle-based therapeutic strategies.European journal of medical research · 2025Review
- Nano-phytochemical-based formulations as promising opportunities for prostate cancer therapy and management: a comprehensive narrative review.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Elucidating the Role of MicroRNA 1827 as Diagnostic Biomarker in Prostate Cancer Progression.Applied biochemistry and biotechnology · 2025Article
- Next-generation Nanomaterial-based phototherapeutic strategies for tumor: from NIR responsiveness to smart activation.Nanomedicine (London, England) · 2025Review
- A branching bivariate weibull distribution model for evaluating exosomes in androgen-deprived agency in the presence of prostate cancer.Scientific reports · 2025Article
- Enhancing the anticancer effects of rosmarinic acid in PC3 and LNCaP prostate cancer cells using titanium oxide and selenium-doped graphene oxide nanoparticles.Scientific reports · 2025Article
- Article
- Article
- Amplification-Free Electrochemiluminescent Biosensor for Ultrasensitive Detection ofCyborg and bionic systems (Washington, D.C.) · 2025Article
- Reviving Dormant Immunity: Millimeter Waves Reprogram the Immunosuppressive Microenvironment to Potentiate Immunotherapy without Obvious Side Effects.Cyborg and bionic systems (Washington, D.C.) · 2025Article
- Robotic Ultrasound Scanning End-Effector with Adjustable Constant Contact Force.Cyborg and bionic systems (Washington, D.C.) · 2025Article
- Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is one of the most prevalent malignant tumors in men worldwide, and early diagnosis is essential to improve patient survival. This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers, including molecular, cellular, and exosomal biomarkers. The potential of various biomarkers such as gene fusions (TMPRSS2-ERG), noncoding RNAs (SNHG12), proteins (PSA, PSMA, AR), and circulating tumor cells (CTCs) in the diagnosis, prognosis, and targeted therapies of prostate cancer is emphasized. In addition, this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications. In addition, this review provides insights into the development of specific probes, including fluorescent, electrochemical, and radionuclide probes, for sensitive and accurate detection of prostate cancer biomarkers. In conclusion, this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research, emphasizing the potential for precision diagnosis and targeted therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.